



President Annual Activity Report for 2025

Anna Sureda, EBMT President

Science



Key achievements in EBMT Working Parties (WPs)

Our [Working Parties](#) achieved notable scientific milestones:

- High-impact cross-Working Party scientific collaborations and publications.
- 121 publications and guidelines in peer-reviewed journals.
- Expansion of registry-based research.
- Delivery of specialised WP-led educational meetings, and EBMT Annual Meeting sessions.
- Establishment of JACIE as a Working Party.

Key publications

[nature](#) > [bone marrow transplantation](#) > [articles](#) > [article](#)

Article | [Open access](#) | Published: 09 September 2025

Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

[R. Greco](#) , [A. Ruggeri](#) , [D. P. McLornan](#), [J. A. Snowden](#), [T. Alexander](#), [E. Angelucci](#), [D. Averbuch](#), [A. Bazarbachi](#), [M. D. Hazenberg](#), [K. Kalwak](#), [M. Kenyon](#), [H. Mekelenkamp](#), [B. Neven](#), [P. Pedrazzoli](#), [Z. Peric](#), [A. M. Risitano](#), [I. Sánchez-Ortega](#), [F. Ciceri](#) & [A. Sureda](#)

Bone Marrow Transplantation **60**, 1499–1525 (2025) | [Cite this article](#)

[nature](#) > [bone marrow transplantation](#) > [perspectives](#) > [article](#)

Perspective | Published: 07 August 2025

Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress

[Donal P. McLornan](#) , [Mette D. Hazenberg](#), [Fabio Ciceri](#), [Tobias Alexander](#), [Emanuele Angelucci](#), [Dina Averbuch](#), [Ali Bazarbachi](#), [Ronjon Chakraverty](#), [Claire Booth](#), [Mirjam H. M. Heemskerck](#), [Ernst Holler](#), [Krzysztof Kalwak](#), [Michelle Kenyon](#), [Per Ljungman](#), [Annarita Miccio](#), [Bénédicte Neven](#), [Simona Pagliuca](#), [Zinaida Peric](#), [Antonio Risitano](#), [Annalisa Ruggeri](#), [Fermin Sánchez-Guijo](#), [Thushan de Silva](#), [John A. Snowden](#), [Gerard Socie](#), ... [Anna Sureda](#)  Show authors

Bone Marrow Transplantation **60**, 1303–1308 (2025) | [Cite this article](#)

1096 Accesses | [7](#) Altmetric | [Metrics](#)

[nature](#) > [bone marrow transplantation](#) > [articles](#) > [article](#)

Article | [Open access](#) | Published: 12 February 2025

The 2023 EBMT report on hematopoietic cell transplantation and cellular therapies. Increased use of allogeneic HCT for myeloid malignancies and of CAR-T at the expense of autologous HCT

[Jakob R. Passweg](#), [Helen Baldomero](#) , [Marina Atlija](#), [Iliana Kleovoulou](#), [Aleksandra Witaszek](#), [Tobias Alexander](#), [Emanuele Angelucci](#), [Dina Averbuch](#), [Ali Bazarbachi](#), [Fabio Ciceri](#), [Raffaella Greco](#), [Mette D. Hazenberg](#), [Krzysztof Kalwak](#), [Donal P. McLornan](#), [Bénédicte Neven](#), [Zinaida Perić](#), [Antonio M. Risitano](#), [Annalisa Ruggeri](#), [Isabel Sánchez-Ortega](#), [John A. Snowden](#) & [Anna Sureda](#)

Bone Marrow Transplantation **60**, 519–528 (2025) | [Cite this article](#)

Advancements in the EBMT Registry

- **37,329** new patients registered: **18,875** allogeneic HCT, **18,504** autologous HCT, and **4,757** CAR-T (consistent with previous years).
- [ISO/IEC 27001:2022 certification](#) achieved, confirming secure data storage and processing standards.
- **Seven Registry releases** introduced new functionality during the year.
- **MicroStrategy** reporting tool migrated to an optimised cloud environment; 10 new reports added.
- **EuroTraCTOR** grant (2022–2025) concluded after contributing significantly to Registry development.
- **Registry Study Manager** successfully piloted and expanded to support Working Parties in managing study data within one platform.

CAR-T Data Collection Initiative

EBMT has actively encouraged centres to report data on patients treated with CAR T-cell therapies to support Post Authorisation Safety (PAS) studies mandated by the EMA.

EBMT is involved in 5 PAS studies where EBMT is responsible for the data collection in these PAS studies performed by the Marketing Authorisation Holders:


1. **Kymriah** (Tisagenlecleucel) by Novartis, including ALL and DLBCL patients – enrolment closed
2. **Yescarta** (Axicabtagene ciloleucel) by Kite-Gilead, including DLBCL and PMBCL patients – enrolment closed
3. **Tecartus** (Brexucabtagene autoleucel) by Kite-Gilead, including MCL patients – enrolment closed
4. **Abecma** (Idecabtagene vicleucel) by BMS-Celgene, including MM patients – enrolment closed
5. **Breyanzi** (Lisocabtagene maraleucel) BMS-Celgene, including DLBCL, PMBCL, HGBCL and FL3B patients – enrolment closed

Although enrolment is closed for these 5 studies, patient follow-up data will need to be collected for 15 years after CAR-T treatment (or until death). More (CAR-T) products and/or additional indications are expected to follow in the near future.


CAR-T Data in the Registry

THE EBMT REGISTRY HOLDS DATA OVER 17,500 CAR T-CELL PATIENTS

The graph below illustrates the steady growth of new reported cases into the EBMT Registry since 2019.



The map below highlights all reporting countries actively contributing data to the EBMT Registry, showcasing the global reach and continuous expansion of our dataset.



Source: EBMT Registry, February 2026

Data cutoff: 2026-02-05 17:20:00

Integration of basic & translational research into EBMT initiatives

EBMT has worked to advance the integration of basic and translational cellular and gene therapy science across all of the society's initiatives.



www.nature.com/bmt

Check for updates

PERSPECTIVE

Advancing the Integration of 'Basic/Fundamental' and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress

Donal P. McLornan^{1,30}, Mette D. Hazenberg^{2,3,30}, Fabio Ciceri⁴, Tobias Alexander⁵, Emanuele Angelucci⁶, Dina Averbuch⁷, Ali Bazarbachi⁸, Ronjon Chakraverty⁹, Claire Booth¹⁰, Mirjam H. M. Heemskerk¹¹, Ernst Holler¹², Krzysztof Kalwak¹³, Michelle Kenyon¹⁴, Per Ljungman¹⁵, Annarita Miccio¹⁶, Bénédicte Neven¹⁷, Simona Pagliuca¹⁸, Zinaida Peric¹⁹, Antonio Risitano²⁰, Annalisa Ruggeri⁴, Fermin Sánchez-Guijo^{21,22}, Thushan de Silva²³, John A. Snowden²⁴, Gerard Socie²⁵, Mirjam Steinbuch²⁶, Luca Vago^{4,27}, Raffaella Greco⁴, Isabel Sánchez-Ortega²⁸ and Anna Sureda²⁹

© The Author(s), under exclusive licence to Springer Nature Limited 2025

Bone Marrow Transplantation (2025) 60:1303–1308; <https://doi.org/10.1038/s41409-025-02688-x>

INTRODUCTION

The mission statement of the EBMT is to function as 'a community of healthcare professionals focused on innovation, research and the advancement of cellular and stem cell-based therapies to save and improve the lives of patients with blood-related disorders'. Since the establishment of the EBMT society in 1974, facilitated by true pioneers within the field, rapid and dynamic progress has been observed across the breadth of haematopoietic cell transplantation (HCT) and cellular/gene therapy practice. Currently we represent a large, diverse, and vibrant community of clinicians (physicians, nursing, and allied health professionals), cellular/gene therapy research scientists, data specialists, statisticians/ bioinformaticians and patient advocates. We must not forget that none of this would have been possible without the foresight, drive and determination of the founding members, which included Eliane Gluckman, Jon Van Rood and Bruno Speck [1]. For a number of years, it has been recognized by the wider community that there needs to be more comprehensive inclusion of basic/fundamental and translational science embedded within core EBMT activities,

educational offerings, and overall strategic goals of the society. Such enhanced interaction will ultimately accelerate future success within our field. There are many examples of translational work impacting immensely on clinical practice for patient benefit over the six decades that HCT has been evolving and in the more recent arenas of chimeric antigen receptor (CAR) T cell and Natural Killer (NK) cell programs and gene therapy. Examples include the pioneering work of Jon van Rood and Els Goulmy on Human Leukocyte Antigens (HLA). Van Rood was, in the 1960's, one of the first to understand the importance of HLA in transplantation science and Goulmy and colleagues amongst the pioneers who demonstrated that killing of donor cells was HLA-restricted in humans [2–5]. In the 1980's, the group of Metcalf and colleagues successfully isolated and cloned G-CSF [6], ultimately leading to use of cytokines as pharmacological agents. More recently, work from many, including Nobel Prize winners Charpentier and Doudna, paved the way for current and future developments in genome editing/CRISPR technology, which have significantly impacted on the entire clinical arena [7]. In the early '2000s',

EU Grants

- **T2Evolve** (CAR/TCR T-cell therapy): EBMT supported consortium work by designing and analysing two Delphi surveys to build expert consensus.
- **Oncode Accelerator**: Ongoing collaboration with the Dutch registry to establish the legal framework and prepare EBMT Registry infrastructure for the Dutch module.
- **EuroTraCTOR**: Developed and piloted a data-extraction tool for EBMT Registry imports with consortium hospitals; project milestones completed and grant successfully closed in 2025.
- **CERTAINTY**: Initiated federated learning (FL) infrastructure for secure distributed data analysis; dataset defined and OMOP data mapping continued.
- **EASYGEN**: Project launched in April 2025; team established, patient advocacy engagement started, and initial scoping and communication planning underway.

Education



Educational initiatives and resources

One of our proudest achievements in 2025 was the establishment of the **EBMT Education Department**, a transformative step in our mission to foster excellence across all professional levels.

- EBMT Physician **Exam** that took place during the Annual Meeting in Florence.
- The EBMT Exam was supported by a comprehensive **preparatory e-Course** to help participants benchmark their knowledge and advance professionally.
- Commitment to making education accessible: the **EBMT Travel Grants** programme aims to ensure that participants from diverse backgrounds have the opportunity to contribute to the exchange of knowledge and ideas within the EBMT community. In 2025, physicians and nurses received travel grants and were able to attend educational events, including the Annual Meeting.

Educational initiatives and resources

In 2025, the EBMT, the EHA and the GoCART Coalition published the second edition of [The EU CAR-T Handbook](#), an extensive open-access resource that covers the most recent developments in CAR-T cell therapies. This updated edition provides more detailed information on scientific advances, clinical applications and evolving regulatory frameworks.



Editors:

Mahmoud Aljurf, Chiara Bonini, Christian Chabannon (editor-in-chief), Julio Delgado, Martin Dreyling, Jurgen Kuball, Annalisa Ruggeri, Marion Subklewe and Anna Sureda

Project Lead:

Isabel Sánchez-Ortega

51st Annual Meeting of the EBMT

The [51st Annual Meeting of the EBMT](#) was held in Florence, Italy, 30 March - 2 April, 2025

- **5,419** in-person registered participants were complemented with **802** virtual registered participants, representing **97** countries.
- We counted with the presence of more than **571** chairs and speakers; high-level science, in the cutting edge of HCT and cellular therapy was delivered in **227** oral presentations and **1,324** posters (printed and e-poster).



23 Educational Meetings in 2025

January	Complications post CAR-T Cell Therapy in Paediatric and Adult Patients	Malaga, Spain
February	JACIE Inspector Training	Rome, Italy
February	EHA-EBMT 7th European CAR T-cell Meeting	Strasbourg, France
March	JACIE Inspector Training	Bern, Switzerland
March - April	51st Annual Meeting of the EBMT	Florence, Italy
April	Inborn Errors Working Party Spring School	Seville, Spain
May	4th Joint ASTCT+EBMT Basic and Translational Scientific Meeting	Lisbon, Portugal
May	2025 China-Europe Scientific Forum on Blood and Marrow Transplantation and Cellular Therapy	Guangzhou, China
May	2025 China-Europe Nursing Forum on Blood and Marrow Transplantation and Cellular Therapy	Guangzhou, China
May	JACIE Inspector Training	Berlin, Germany
June	Paediatric Diseases Working Party Educational Course	Wroclaw, Poland

September	10th International Transplant and Cellular Therapy Course	Barcelona, Spain
September	Advancements in cellular therapy for Autoimmune Diseases and Chronic Haematological Malignancies	Rome, Italy
September	Inborn Errors Working Party Annual Conference	Freiburg, Germany
October	Transplant Complications Working Party Educational Meeting	Dubrovnik, Croatia
October	17th Educational Meeting of the EBMT Nurses Group	Nantes, France
October	7th EBMT Statistical Course	Leiden, Netherlands
October	Acute Leukaemia and Cellular Therapy and Immunobiology Working Parties Joint Transplant Programme Track at the 8th Annual Meeting of the IACH	Paris, France
October	Severe Aplastic Anaemia Working Party Educational Course	Basel, Switzerland
November	Lymphoma Working Party Educational Course	Paris, France
November	7th International Conference on Relapse After Transplant and Cellular Therapy (HSCT ²)	Madrid, Spain
November	28th Infectious Diseases Working Party Educational Course	Würzburg, Germany
November	Haemoglobinopathies Working Party Annual Meeting	Regensburg, Germany

GvHD Alliance

- EBMT strengthened its leadership in graft-versus-host disease (GvHD) through the **GvHD Alliance**, a multi-stakeholder initiative improving prevention, diagnosis, management, and long-term follow-up across Europe.
- **European expansion** advanced in 2025, including a launch meeting in June bringing together clinicians, researchers, patient advocates, and caregivers around a shared roadmap and patient-centred care approach.
- The Alliance promotes education, expert exchange, and best-practice dissemination, including digital resources, webinars, training content, and an online knowledge hub.
- Supports collaboration, data-driven research, and wider awareness to improve GvHD care.
- Focus on expanding access to high-quality GvHD information across countries, including localisation and broader engagement of the transplant community.

Patient Care & Advocacy



JACIE 

Governance change: from a Committee to a Working Party

- **JACIE became an EBMT Working Party** following approval at the EBMT General Assembly 2025, gaining permanent representation on the **Scientific Council and Board of Association**.
- **Governance restructured** to align with the WP framework, with the WP Board comprising representatives from all JACIE Committees and Task Forces.
- **Joaquim Vives** joined the WP Board as the ISCT representative, succeeding **Fermin Sanchez-Guijo Martin** (summer 2025).
- **Leadership transition: Lynn Manson** stepped down as first WP Chair (October 2025); **Charles Crawley** appointed Interim WP Chair.
- While governance restructuring has been challenging, it has **enabled broader discussion of JACIE's publication and educational strategy**.

JACIE activity update

- The number of **applications** reduced significantly in 2025. This is due to the impact of Covid in 2021-22. As the certification cycle is four years, centres due to apply for re-certification was understandably low in 2025.
- JACIE carried out **93 inspections** in 2025 (91 in 2024). In addition, JACIE collaborated in three joint inspections with FACT under Stepwise initiative in Latin America. JACIE also expanded its geographical reach with first JACIE inspections in India and China.
- The high level of inspection activity for the last two years was also reflected in the increase in the number of **certifications** in 2025: a total of **84** centres completed the certification process in 2025 (71 in 2024).

Publication of the 9th Edition of HCT and 3rd Edition of IEC Standards

- FACT and JACIE published updated Standards in October 2025: the [9th Edition of HCT Standards and the 3rd Edition of IEC Standards](#), marking a major milestone in the continuous effort to promote quality, safety, and excellence in cellular therapy worldwide.
- The revised Standards reflect the **rapid scientific, clinical, and regulatory developments** in the field.
- **EBMT and JACIE thank** the Standards Development Sub-Committee, contributors, centres, and public consultation participants for their **expertise, commitment, and voluntary contributions**, supporting the highest levels of patient care worldwide.

Inspectors' activities

- In 2025, **three Inspector Training Courses** were delivered:
 - 5 February, **Rome**, Italy, in conjunction with Centro Nazionale Trapianti (**CNT**)
 - 7 March, **Bern**, Switzerland, with Swiss Blood Stem Cell Transplantation and Cellular Therapy (**SBST**)
 - 26 May, **Berlin**, Germany, with Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzelltransplantation und Zelluläre Therapie (**DAG-HSZT**)
- JACIE also continued its **grants programme** to support inspectors' participation in the Annual Meeting 2025. The initiative continues to provide valuable opportunities for **learning**, **networking**, and **collaboration**, and remains a much valued Inspector incentive. In total, **77 grants** were awarded, enabling inspectors to attend the meeting either in person or virtually.

JACIE Committees' activities

- The [Inspector Committee](#) (JIC) delivered five Inspectors' webinars with updates on the Standards and inspection process; sessions were live and recorded to ensure broad, ongoing access.
- The [Quality Managers Committee](#) (QMC) co-published a paper with the GOCART Coalition (November 2025), based on a January 2025 survey of 146 institutions across Europe and beyond.
 - View the publication titled: [Operational burden and fragmented implementation in CAR T-cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee](#)
- The QMC also launched its **podcast series “Inside JACIE: Quality in Practice”**, for HCT professionals navigating certification, continuous improvement, and the evolving landscape of stem cell therapy.

The Nurses Group

Nursing leadership across EBMT Meetings

- 650 registered nurses to the [51st Annual Meeting of the EBMT](#) in Florence
 - 197 nursing abstracts submitted
 - Programme aligned to four pillars: Clinical Practice | Research | Education | Leadership
 - Next Generation Session: one of the most attended sessions
- [17th EBMT Nurses Group Educational Meeting](#) (Nantes), strong partnership with the French Nurses Group
- Dedicated [nurses' tracks](#) at:
 - European CAR T-cell Meeting
 - International Transplant & Cellular Therapy Course
- Active contribution to EBMT Working Party sessions

Education resources and career development

- For the first time, the NG also contributed to **Practice Harmonisation & Guidelines**, leading a workshop on the role of palliative and supportive care in HCT and CT.
- A fifth translation of the [EBMT Textbook for Nurses](#) was published in 2025, supported by the Polish National Nurses Group and DMKS.
- [Preparatory Course](#) for the 2026 NG [Exam](#) was successfully launched.
- **International collaborations** continued to grow, with monthly webinars and activities with colleagues in South Africa and Sri Lanka, and other partner societies.
- **Three expert-led educational videos** were developed, covering bone marrow aspiration and trephine biopsy, the insertion and management of peripherally inserted central catheters (PICCs), and the thawing and infusion of cryopreserved stem cells and CAR T-cells. [Nurses' Practical Skills Videos](#).



GoCART

COALITION

Joint initiative by EBMT and EHA to advance cellular therapies through multi-stakeholder collaboration

GoCART Coalition: Key Achievements in 2025

1. Data Harmonisation

- Supported revision of the EBMT cellular therapy data form with input from European stakeholders
- Continued collaboration with T2Evolve on harmonised CAR-T core data set (CART-CD) using the Delphi process and joint stakeholder workshops to drive consensus on data standards

2. Standards of Care

- Survey conducted with JACIE Quality Managers Committee to optimise CAR-T care pathways
 - Identified overlapping requirements and areas for harmonisation
 - Results presented at EBMT 2025 Annual Meeting and published in [HemaSphere](#)

3. Education & Training

- Released 2nd Edition of [the EU CAR-T Handbook](#)
- Progress on developing the [CAR-T Passport](#) of harmonised core training. (Launched in Feb. 2026).
- Launched pilot GoCART [Observership Programme](#) for emerging CAR-T centres

GoCART Coalition: Key Achievements in 2025

4. Policy & Advocacy

- Joint statements published on key regulatory topics:
 - [Hospital Exemption for ATMPs](#)
 - [FDA REMS](#) changes and implications for Europe
- Engaged EU stakeholders on evolving CAR-T regulatory frameworks particularly around the EU's new regulation on SoHO which comes into effect mid-2027

5. Scientific Excellence

- Promoted use of EBMT Registry and real-world data for collaborative research
- Supported 11 GoCART studies
- Publications presented at international meetings and in peer-reviewed journals

Society's Updates



Elections 2025



EBMT President-Elect
Ibrahim Yakoub-Agha



EBMT Inborn Errors Working Party
Maria Ester Bernardo



EBMT Transplant Complications Working Party
Olaf Penack



JACIE Working Party Chair
Lynn Manson

(Resigned in Oct. 2025 - Charles Crawley appointed by EBMT Board as interim JACIE WP coordinator until March 2026.)

New Managing Director at EBMT

- EBMT has appointed **Yann Mahé** as its new Managing Director (Feb 2026).
- Yann brings **~20 years of leadership experience** across scientific, medical information, technology, and publishing sectors.
- Previously held **senior roles in IT innovation, project management, sales, and marketing**, leading international and multidisciplinary teams.
- At EBMT, he will focus on **implementing the society's scientific strategy**, strengthening collaboration, and **enhancing EBMT's global impact in research and education**.
- The goal is to **better support the scientific and clinical community** through high-quality data, research, and educational initiatives.



Paris Office move

- **EBMT Paris Study Unit Staff** moved to a new office in December 2025, after 20+ years at Hôpital Saint Antoine. ([Paris Study Unit Office](#))
- This relocation is a key component of our Global Infrastructure Project, aimed at creating a **unified and independent EBMT organisation**.
- The new Paris office allows **independent IT operations**, improving efficiency and strategic delivery.
- This transition **supports our mission** to foster greater collaboration and communication across the organisation, ensuring we can continue to grow and innovate.

Transformation and Consolidation Project

As EBMT continues to evolve, we have taken important steps to strengthen the organisation for the future. The Transformation and Consolidation Project, initiated in early 2025, is reinforcing EBMT's long-term resilience, improving how we operate across the organisation, and strengthening the foundations that support our mission. Underpinning these efforts is our shared commitment to keep science at the centre of everything we do. This has been a shared effort across the organisation, with important changes already underway and further steps planned for 2026.

EBMT PARTNERS

The EBMT would like to thank the 17 corporate partners for their generous support in 2025

Distinguished Partners of Excellence

Celgene | A Bristol-Myers Squibb Company

Long-term Partners of Excellence

Autolus



kyowa KIRIN

NOVARTIS

sanofi

VERTEX

Other Partners of Excellence

ALEXION®
AstraZeneca Rare Disease

CSL Behring
Biotherapies for Life®



Jazz Pharmaceuticals

medac



OMEROS

orcabio



TSCAN
THERAPEUTICS

Thank you



Contact Me



Email: asureda@iconcologia.net



52nd Annual Meeting

Madrid, Spain

22-25 March 2026

Advancing the Art of Patient Care

#EBMT26